SOURCE: TyRx Pharma, Inc.

August 11, 2008 09:30 ET

TyRx Pharma, Inc. to Present at the Canaccord Adams 28th Annual Global Growth Conference

MONMOUTH JUNCTION, NJ--(Marketwire - August 11, 2008) - TyRx Pharma, Inc., a leader in the commercialization of implantable combination drug/device products, announced today that William Edelman, CEO, will present at the Canaccord Adams 28th Annual Global Growth Conference on Tuesday, August 12, 2008 at 10:30 am (ET) at the Boston Intercontinental Hotel.

TyRx announced, on May 14th, the first commercial implant of the AIGISRX™ Anti-Bacterial Envelope in a CRMD procedure conducted at St. Luke's Episcopal Hospital of the Texas Heart Institute in Houston following its FDA clearance earlier this year. Since that time, over 250 AIGISRX™ implants have been performed nationally in many of the top 100 teaching hospitals throughout the U.S. (United States Department of Health and Human Services, 2006).

On February 27th, 2008, TyRx announced that the Company raised $25 million in a venture capital financing led by Clarus Ventures and co-led by Pappas Ventures.

About TyRx Pharma, Inc.

TyRx Pharma, Inc., an ISO 9001:2000 and ISO 13485:2003 certified medical device manufacturer, commercializes implantable combination drug/device products utilizing novel biomaterials, including technology licensed exclusively from Rutgers, The State University of New Jersey. Additionally, TyRx has exclusively licensed from Baylor College of Medicine and The University of Texas M. D. Anderson Cancer Center product patents and associated technologies to address the problem of postsurgical nosocomial infection. TyRx is deploying its capabilities across a broad range of combination implantable drug/devices. The combination products sector (products incorporating both a drug & a device component) is expected to be the highest growth segment of the medical products industry and TyRx is positioned to be an innovative applications leader in the space.

For more information, please visit

Contact Information

  • Contact:

    William Edelman
    TyRx Pharma, Inc.
    Office: 732-246-8676
    Direct: 732-964-1101
    Cell: 617-759-5451
    Email Contact: Email Contact